February 15, 2010 - New data released shows targeted radiotherapy, using real-time prostate tumor tracking during external beam radiation, enables the delivery of high doses of radiation, while reducing treatment-related side effects, including bowel urgency, rectal irritation and urinary irritation.

The study, which was presented at the 51st annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), November1-4,2009, was significant because radiation for prostate cancer is often delivered without real-time tracking, which can result in the morbidities due to unintended irradiation of healthy tissue. The tumor tracking technology works similar to the GPS system in cars and is installed in more than 90 medical centers nationwide.
 
The objective of the study was to investigate whether patient-reported quality of life after high-dose external beam intensity-modulated radiotherapy for prostate cancer can be improved by decreasing planning target volume margins while using real-time tumortracking.

In the study, patients underwent radiotherapy with nominal 3-mm margins and electromagnetic real-time tracking. Morbidity was assessed before and at the end of radiotherapy using Expanded Prostate Cancer IndexComposite (EPIC) questionnaires. Changes in scores were compared between the Assessing Impact of Margin Reduction(AIM) study cohort and the comparator PROST-QAcohort, treated with conventional margins.

The authors concluded that prostate cancer patients treated with reduced margins and tumor tracking had less radiotherapy- related morbidity than their counterparts treated with conventional margins. Highlycontoured intensity-modulated radiotherapy shows promise as a successful strategy for reducing morbidity in prostate cancer treatment.

Reference: Sandler, H, et al. Reduction in Patient-reported Acute Morbidity in Prostate Cancer Patients Treated With 81-Gy Intensity-modulated Radiotherapy Using Reduced Planning Target Volume Margins and Electromagnetic Tracking: Assessing the Impact of Margin Reduction Study.

 


Related Content

News | Women's Health

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...

Time November 04, 2025
arrow
Feature | Kyle Hardner

Radiotherapy contributes to about 40% of all cancer cures but still lags behind systemic therapy in funding and ...

Time October 21, 2025
arrow
News | Radiation Oncology

Sept. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT has announced ...

Time September 05, 2025
arrow
Feature | Artificial Intelligence

Brain metastases are 10 times more common than primary brain tumors, occurring in 10 to 20% of adult patients with ...

Time September 04, 2025
arrow
News | Ultrasound Imaging

Aug. 8, 2025 — Memorial Hermann-Texas Medical Center announced it will begin using a new FDA-approved ultrasound device ...

Time August 11, 2025
arrow
News | Radiation Oncology

May 2, 2025 — GE HealthCare has announced an intended expansion of its radiation oncology portfolio as well as the ...

Time May 03, 2025
arrow
News | Radiology Education

April 21, 2025 — On June 20, the American Society of Radiologic Technologists (ASRT) will award Life Member status to ...

Time April 21, 2025
arrow
News | Radiology Business

April 16, 2025 — According to a new report, the U.S. Radiotherapy Market is projected to reach $2.49 billion by 2030 ...

Time April 17, 2025
arrow
News | ASTRO

March 14, 2025 — Another pivotal milestone in the nation’s fight against cancer recently took place with the ...

Time March 17, 2025
arrow
News | Computed Tomography (CT)

Royal Philips recently received 510(k) clearance from the US Food and Drug Administration (FDA) for its detector-based ...

Time November 13, 2024
arrow
Subscribe Now